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Longitudinal decline in lung 
function: a community-based 
cohort study in Korea
Ah Young Leem1, Boram park2, Young Sam Kim1, Joon chang1, Sungho Won  2 & Ji Ye Jung1
progressive decline in lung function is the hallmark of chronic obstructive pulmonary disease (copD). 
We aimed to assess the rate of decline in forced expiratory volume in 1 second (FEV1) in patients from a 
community cohort database in Korea. 5,865 subjects aged 40–69 years from the Ansung-Ansan cohort 
database I–III (2001–2006) were included in this study. We assessed the annual rate of decline in FEV1 
over time in relation to smoking status, patient sex, and presence or absence of pre-bronchodilator 
airflow limitation using a generalized additive mixed model. The mean follow-up duration was 3.8 
years. The annual mean decline in FEV1 in the entire cohort was significantly more rapid for men than 
women (31.3 mL vs 27.0 mL, P = 0.003). Among men without pre-bronchodilator airflow limitation, 
annual mean declines in FEV1 were 31.5, 35.5, and 40.1 mL for never smokers, former smokers (P = 0.09 
vs. never smokers), and current smokers (P < 0.001 vs. never smokers), respectively; and 23.4, 19.7, and 
33.9 mL, respectively, for men with pre-bronchodilator airflow limitation. Thus, among Korean males, 
smoking accelerates lung function decline over time whereas smoking cessation slows the rate of FEV1 
decline regardless of pre-bronchodilator airflow limitation. This underscores the importance of smoking 
cessation in Koreans.
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and increased medi-
cal expenses worldwide1,2. Currently, COPD is the fourth leading cause of death and is predicted to become the 
third leading cause of death by 20303. Fletcher and Peto reported that exposure to tobacco smoke accelerates the 
age-related decline in lung function as assessed by the forced expiratory volume in 1 second (FEV1), leading to 
clinical disease4. Since then, several population studies have supported this causal link, and therapeutic clinical 
trials have targeted reductions in the rapid decline in FEV13,5–10. However, observed declines in FEV1 in these 
trials and in observational cohorts of patients with COPD have been variable, particularly among patients with 
severe airflow limitation3,5–14.
Cigarette smoking is the most important risk factor for acceleration of lung function decline15. Lung damage 
in smokers is characterized by inflammation and airway remodelling leading to airflow limitation and destruction 
of the lung parenchyma16. The underlying lung characteristics may vary; moreover, smokers differ in their suscep-
tibility to emphysema or bronchitis17,18. The strongest and most consistent detrimental effect from smoking has 
been found in current smokers and has been shown to decrease over time after smoking cessation15,19.
However, COPD results from a complex interaction between genes and the environment. Cigarette smoking 
is the leading environmental risk factor for COPD, but <50% heavy smokers develop COPD during their life-
times20. Genetic factors, age, sex, and exposure to particles are also risk factors21. Furthermore, any factor that 
affects lung growth has the potential to increase an individual’s risk of developing COPD. In previous studies, the 
birth weight and FEV1 in adulthood were positively associated, and factors in early life seem to be as important as 
heavy smoking for the prediction of lung function in adult life22.
A progressive decline in lung function has been considered the hallmark of COPD. It is also possible that a 
normal decline in FEV1 could lead to COPD. A recent study by Lange et al. analysed three different longitudinal 
cohorts and reported that approximately 50% of patients developed COPD because of an accelerated decline in 
FEV1 over time, while the other 50% developed COPD because of abnormal lung development and growth23. 
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Relatively few studies evaluating the decline in lung function in healthy subjects have been reported in Asia24. 
Therefore, the present study aimed to evaluate the rate of decline in FEV1 in patients selected from a community 
cohort database in Korea.
Results
Baseline characteristics. Of the initial 8,842 participants in the Ansung-Ansan cohort, 7,111 (80.4%) 
underwent at least two pulmonary function tests and were included in this study. Valid data for the smoking his-
tory were available for 5,865 of the 7,111 subjects, revealing 3,979 never smokers, 686 former smokers, and 1,200 
current smokers (Fig. 1). The mean (standard deviation) follow-up duration was 3.8 (0.7) years. Table 1 shows the 
distribution of subjects in the different groups stratified by sex, lung function, and the smoking status.
Baseline characteristics of the study population are shown in Table 2. Of the 5,865 subjects, 2,376 (40.5%) were 
men and 3,489 (59.5%) were women. The proportions of male and female never smokers were 23.4% and 98.1%, 
respectively, while those of male and female current smokers were 47.9% and 1.8%, respectively. The mean abso-
lute FEV1 value was 3.4 L for men and 2.5 L for women. Over 80% subjects were followed up for 4 years.
Rate of decline in FEV1 in healthy never smokers. Figure 2 shows the decline in FEV1 with age in male 
and female never smokers without obstructive lung disease (OLD). Men exhibited higher absolute FEV1 values 
than did women at all time points. The annual rate of decline was significantly more rapid for male healthy never 
smokers (31.3 mL; 95% confidence interval [CI], 28.5–34.1) than for their female counterparts (27.0 mL; 95% CI, 
25.9–28.1; P = 0.003).
Effect of smoking on the decline in lung function. Figure 3 compares the decline in FEV1 among male 
healthy never smokers, former smokers with and without OLD, and current smokers with and without OLD. The 
baseline characteristics of the subjects are shown in Supplementary Table 1. The annual rate of decline in FEV1 
was the fastest for current smokers (43.8 mL; 95% CI, 39.6–47.9; P < 0.001 vs. healthy never smokers and former 
smokers), while it was more rapid for former smokers (36.9 mL; 95% CI, 32.5–41.5; P = 0.023) than for healthy 
never smokers (31.8 mL; 95% CI, 28.4–35.2; Fig. 3). It also tended to be more rapid for current smokers (32.0 mL; 
95% CI, 25–2–38.8) than for healthy never smokers (27.2 mL; 95% CI, 26.2–28.2; P = 0.165).
Figure 4 shows the comparisons among male healthy never smokers, healthy former smokers, healthy current 
smokers, former smokers with OLD, and current smokers with OLD. The baseline characteristics of the subjects 
Figure 1. Flow chart showing the patient selection process for the study.
Smoking status
Men Women
Healthy OLD Healthy OLD
Never smoker 521 36 3,297 125
Former smoker 595 86 5 0
Current smoker 968 170 52 10
Total 2,084 292 3,354 135
Table 1. Distribution of subjects in different groups categorized by sex, lung function and smoking status. 
Abbreviations: OLD, obstructive lung disease.
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Characteristics
Men
(n = 2,376)
Women
(n = 3,489)
Age, years 51.0 ± 8.4 52.3 ± 8.8
Height, cm 167.1 ± 5.7 154.0 ± 5.5
Weight, kg 68.3 ± 9.4 59.1 ± 8.3
BMI, kg/m2 24.4 ± 2.8 24.9 ± 3.2
Smoking status
  Never smoker 557 (23.4) 3,422 (98.1)
  Former smoker 681 (28.7) 5 (0.1)
  Current smoker 1,138 (47.9) 62 (1.8)
Lung function
  FEV1, L 3.4 ± 0.6 2.5 ± 0.5
  FEV1, % of the predicted value 107.0 ± 15.1 117.0 ± 17.3
  FVC, L 4.3 ± 0.7 3.1 ± 0.6
  FVC, % of predicted value 102.6 ± 13.2 107.5 ± 14.8
  FEV1/FVC ratio, % 78.4 ± 7.9 81.7 ± 6.4
Follow-up duration
  2 years 383 (16.1) 486 (13.9)
  4 years 1,993 (83.9) 3,003 (86.1)
Table 2. Baseline characteristics of patients in the Ansung-Ansan cohort who had valid smoking history data 
(n = 5,865). Notes: Data are presented as numbers (%) or means ± standard deviations. Abbreviations: BMI, 
body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Figure 2. Comparison of the annual mean decline in FEV1 for healthy male (n = 521) and female (n = 3,297) 
never smokers. The annual mean decline in FEV1 is 31.3 mL (95% CI, 28.5–34.1) for men and 27.0 mL (95% CI, 
25.9–28.1) for women (P = 0.003). Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 
1 second.
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are shown in Supplementary Table 2. Figure 4A compares the decline in FEV1 among male healthy never smok-
ers, healthy former smokers, and healthy current smokers. The annual rate of decline in FEV1 was the fastest for 
healthy current smokers (40.1 mL; 95% CI, 37.0–42.2; P < 0.001 vs. healthy never smokers; P = 0.025 vs. healthy 
former smokers), while it was statistically indistinguishable between healthy former smokers (35.5 mL; 95% CI, 
33.2–37.8 mL) and healthy never smokers (P = 0.098).
Figure 4B compares the decline in FEV1 among male healthy never smokers, former smokers with OLD, and 
current smokers with OLD. The annual rate of decline in FEV1 was significantly more rapid for current smok-
ers with OLD (33.9 mL; 95% CI, 30.2–37.6) than for former smokers with OLD (19.7 mL; 95% CI, 15.1–24.3; 
P = 0.009), while there was no significant difference between healthy current smokers and current smokers with 
OLD (Fig. 4C).
Discussion
In the present study, the annual decline in lung function was estimated for a population-based cohort in Korea. 
Healthy men and those with OLD who were current smokers showed a significantly increased rate of decline in 
FEV1 than did their former smoker counterparts. The rate of decline in FEV1 was similar between former smok-
ers and never smokers among men without OLD and between male healthy current smokers and male current 
smokers with OLD.
Studies of the decline in lung function in population-based cohorts have been previously reported25,26. The 
mean decline in FEV1 in healthy never smokers in our study was similar to that in the European Community 
Figure 3. Comparison of the annual mean decline in FEV1 among male healthy never smokers (n = 521), 
former smokers (with and without OLD; n = 681), and current smokers (with and without OLD; n = 1138). 
Current smokers (43.8 mL) showed the fastest annual rate of decline in FEV1, followed by former smokers 
(36.9 mL) and healthy never smokers (31.8 mL), sequentially. Abbreviations: OLD, obstructive lung disease; CI, 
confidence interval; CS, current smoker; FEV1, forced expiratory volume in 1 second; FS, former smoker; NS, 
never smoker.
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Respiratory Health Survey (ECRHS)26. We found annual mean FEV1 declines of 31.8 mL for men and 27.2 mL 
for women, while the ECRHS reported respective decreases of 32 mL and 24 mL26. Although the participants in 
our study were older than those in the ECRHS, they were taller on average. The average annual decline in FEV1 
in current smokers in our study was consistent with that in the Swiss Study on Air Pollution and Lung Diseases 
in Adults, where the annual mean decline in FEV1 was 43.8 mL for male current smokers and 34.7 mL for their 
female counterparts (43.7 mL for men and 32.0 mL for women in our study)25. Omori et al. reported similar 
declines in FEV1 in the Japanese male population stratified by age and the smoking status24.
Several previous reports have analysed the relationship between declining lung function and smoking status in 
healthy subjects25,27–33. The natural history of COPD has been determined mainly from the study by Fletcher and 
Peto, who evaluated the decline in lung function in 1,136 working men aged 35–59 years over an 8-year follow-up 
period4. On the basis of a limited number of observations, these authors proposed that the decline in FEV1 was 
significantly accelerated in a subgroup of smokers4. Kohansal et al. found that current smoking increased the rate 
of decline in FEV1 in a large cohort of men and women31. Our study confirmed that tobacco smoking increased 
the rate of decline in lung function in men. However, the number of female current smokers in our study was too 
small for the detection of a statistically significant difference between current smokers and healthy never smokers.
Fletcher and Peto considered that the rate of decline in FEV1 would normalize after smoking cessation at any 
age4. Many studies have reported beneficial effects of smoking cessation on lung function decline27,31,34. We found 
that the rate of decline in FEV1 in men was not different between healthy never smokers and healthy former 
smokers. In the study by Kohansal et al., smoking cessation had a beneficial effect at any age, although it was more 
pronounced in earlier quitters31. The rate of decline in FEV1 in both men and women who smoked but quit before 
the age of 30 years was similar to that in healthy never smokers31.
In the present study, the rate of decline in FEV1 in current smokers with OLD was similar to that in healthy 
never smokers and healthy current smokers. In a population-based cohort from three cities in Latin America, the 
annual mean post-bronchodilator decline in FEV1 was 27 mL for patients with COPD at baseline and 36 mL for 
those without COPD32. A more rapid decline was associated with older age, higher baseline lung function, and 
smoking at baseline32. A greater decline in FEV1 in men and patients with better lung function suggests that the 
decline is proportional to lung size32,33. In a study by Ware et al., the annual rate of decline was greater for elderly 
nonsmokers (12.9 mL at the age of 25 years vs. 58.2 mL at the age of 75 years)35.
Figure 4. Comparison of the annual mean decline in FEV1 according to the smoking status and presence or 
absence of OLD in men. Notes: (A) Comparison of the annual mean decline in FEV1 among healthy never 
smokers (n = 521), healthy former smokers (n = 595), and healthy current smokers (n = 968). The annual rate 
of decline in FEV1 is the fastest for healthy current smokers (40.1 mL). (B) Comparison of the annual mean 
decline in FEV1 among healthy never smokers (n = 521), former smokers with OLD (n = 86), and current 
smokers with OLD (n = 170). The annual rate of decline in FEV1 is the slowest for former smokers with OLD 
(19.7 mL). (C) The annual mean decline in FEV1 is comparable between healthy current smokers (n = 968) and 
current smokers with OLD (n = 170). The annual rate of decline in FEV1 is faster in healthy current smoker than 
in healthy never smoker (40.1 mL vs. 31.8 mL; P < 0.001). Abbreviations: CI, confidence interval FEV1, forced 
expiratory volume in 1 second; OLD, obstructive lung disease.
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Several studies evaluating the decline in lung function in Korean patients with COPD have been published36,37. 
Kim et al. reported that the adjusted annual rate of decline in the postbronchodilator FEV1 was 28.3 mL, with no 
significant difference in the rate of decline in lung function among groups stratified according to the 2014 Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (−34.4 ± 7.9 [group A], −26.2 ± 9.4 [group 
B], −22.7 ± 16.0 [group C], and −24.0 ± 8.7 mL/year [group D])36. The decline that we report in healthy never 
smokers was more rapid than that in former smokers with OLD, and slower than that in current smokers with 
OLD. This discrepancy may be attributable to baseline FEV1 differences between the two studies; the airflow 
limitation in smokers with OLD in the present study was milder than that in the GOLD A group in the study by 
Kim et al. Small number of former smokers with OLD might not represent real lung function decline of former 
smokers with OLD. However, in the group of former smoker with OLD, absolute FEV1 at 40 years was lower than 
in the group of healthy never smoker. Therefore, the amount of decline of FEV1 might be less in the group of for-
mer smoker with OLD because healthy never smokers have more to lose than former smokers with OLD in early 
stage. In another study, the annual post-bronchodilator FEV1 declined more rapidly in older patients with COPD 
(25.0 mL for patients older than 67 years vs. 13.0 mL for younger patients)37. However, the rate of decline in lung 
function in the healthy population in Korea has not been reported. We investigated the effect of smoking and 
smoking cessation on the normal decline in lung function over time in a large cohort of both men and women, 
including healthy never smokers.
Our study has some strengths and potential limitations. The main strengths include its prospective design and 
the inclusion of spirometric measurements for a large population-based cohort including both rural and urban 
communities. However, the study duration was relatively short. Given that half the subjects were aged 40–49 
years, they would have still been younger than 55 years after a mean follow-up period of 3.8 years. However, the 
Ansung-Ansan cohort study is ongoing, and we hope to analyse the data further with a longer follow-up period. 
Moreover, we used pre-bronchodilator spirometric values rather than post-bronchodilator values; accordingly, 
we used OLD for patient stratification instead of COPD. In addition, data concerning smoking cessation were 
purely based on a questionnaire, with no objective confirmation using a biological method. Self-reporting of the 
smoking status may be biased by societal factors, because women are less likely to report their smoking status 
because of the fear of stigma. Moreover, the duration of smoking in pack-years, and the mean number of years 
since smoking cessation could not be analysed because of the lack of data. Furthermore, because of the lack of 
information such as birth weight, we could not evaluate the impact of lung underdevelopment on lung func-
tion. In addition, the number of women in all groups except for the healthy never smoker group was very small. 
Because the analysis of these groups might result in very unreliable estimates, only healthy never smokers were 
analysed. Finally, we could not exclude the participants with a restrictive pattern on spirometry.
In conclusion, the present study demonstrated the rate of decline in lung function over time in a large 
community-based Korean cohort. The findings suggest that continued smoking accelerates the decline in lung 
function, regardless of the presence of OLD. This underscores the importance of smoking cessation in the Korean 
population.
Methods
Study populations. The ongoing Ansung-Ansan cohort study was initiated in 2001 and supported from 
the National Genome Research Institute (Korea Centers for Disease Control and Prevention). It is a part of the 
Korean Genome and Epidemiology Study, which is based on a series of large community-based epidemiological 
surveys investigating chronic disease in Koreans. Further information on the study design and protocols have 
been published previously38,39.
From Ansung-Ansan cohort I (2001–2002), 8,842 subjects aged 40–69 years with valid lung function meas-
urements and no previous history of asthma, bronchiectasis, or lung destruction, were included. Follow-up 
examinations and surveys are performed biennially (Fig. 1). We analysed data from a baseline survey and two 
subsequent biennial surveys (I–III: 2001–2006). Of the 8,842 subjects in the Ansung-Ansan cohort I, 7,111 who 
underwent pulmonary function testing ≥2 times during surveys I–III were used as the study population in the 
present research. Valid data concerning the smoking history were available for 5,865 of the 7,111 subjects.
The Korea Centers for Disease Control and Prevention obtained written informed consent from all partici-
pants on collection of the data, and the Institutional Review Board of Severance Hospital approved the present 
study protocol (4-2016-0458). All methods were performed in accordance with the approved protocol and with 
the relevant guidelines and regulations.
Spirometry. Lung function was assessed using spirometry (VMAX2130, SensorMedics Corporation, Yorba, 
CA, USA) at baseline and the first and second follow-up visits. Spirometry was performed according to American 
Thoracic Society/European Respiratory Society guidelines40.
Definition. Individuals who declared that they had never smoked before the study were considered never 
smokers, those who declared that they had smoked but stopped before the study were considered former smok-
ers, and those who reported active smoking during the study period were considered current smokers. OLD was 
defined by a pre-bronchodilator FEV1/forced vital capacity ratio of <0.7. Individuals without OLD were consid-
ered healthy subjects.
Statistical analysis. We stratified participants into groups according to the smoking status (never smoker, 
former smoker, and current smoker) at cohort inception and the presence or absence of OLD. Subjects who did 
not respond to the questionnaires for the smoking history were excluded, while those with consistent reporting 
of the smoking history were included and categorized into never, former, and current smokers. Subjects whose 
smoking status changed from current smoker to former smoker during the study period were categorized as 
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former smokers. We then determined the rate of decline in FEV1 over time according to the smoking status, sex, 
and OLD status in subjects for whom two or more spirometry measurements were available.
The FEV1 values measured at each assessment were analysed using linear mixed models. We included age, sex, 
the body mass index, height, the smoking status, and the interaction of age and smoking as covariates. The model 
for all subjects i at time point j was as follows:

 ~ ~
β β β β β
σ
= β + + + + + ⋅ + +
.. Σ
FEV age sex BMI smoking status age smoking status b
where MVN b iid MVN
,
( , , ) (0, ), (0, ),
ij i ij i ij
ij
t
i
1 0 1 2 3 4 5
ij
2
ij
n1
while the model for female or male sex was as follows:

 ~ ~
β β β β
σ
= β + + + + ⋅ + +
.. Σ .
FEV age BMI smoking status age smoking status b
where MVN b iid MVN
,
( , , ) (0, ), (0, )
ij ij i ij
ij
t
i
1 0 1 2 3 4
ij
2
ij
n1
Generalized additive mixed models41 were used to determine the best fit for the decline in FEV1 over time, 
and all figures were generated from these models. All statistical analyses were performed using R version 3.4.3 (R 
Foundation for Statistical Computing, Vienna, Austria). For the linear mixed models and the generalized linear 
mixed models, the “nlme” and “mgcv” packages, respectively, were used.
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